Incretin-based therapies, including GLP-1 and GIP analogues, have proven effective in ameliorating excitotoxic neuronal damage, a common consequence of both traumatic and nontraumatic brain injuries [9, 10]. The gene discussed is GCG; the disease is brain injury.